US2009148469A1PendingUtilityA1

Multicomponent meningococcal vaccine

55
Assignee: ROBINSON ANDREWPriority: Nov 2, 1998Filed: Oct 20, 2008Published: Jun 11, 2009
Est. expiryNov 2, 2018(expired)· nominal 20-yr term from priority
Inventors:Andrew RobinsonAndrew Richard GorringeMichael John HudsonKaren Margaret Reddin
C07K 14/22A61K 39/095A61K 38/164A61P 31/04
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.

Claims

exact text as granted — not AI-modified
1 . A composition comprising  N. meningitidis  outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. 
     
     
         2 . The composition of  claim 1 , wherein said antigenic component is an  N. meningitidis  antigenic protein. 
     
     
         3 . The composition of  claim 2 , wherein said outer membrane vesicles are from a first strain of  N. meningitidis  and said antigenic component is from a second strain of  N. meningitidis  different from the first. 
     
     
         4 . The composition of  claim 1 , wherein said outer membrane vesicles are enriched with a plurality of antigenic components from different strains of  N. meningitidis.    
     
     
         5 . The composition of  claim 1 , wherein said outer membrane vesicles comprise a mixture of outer membrane vesicles from different strains of  N. meningitidis.    
     
     
         6 . The composition of  claim 1 , wherein said antigenic component is an  N. meningitidis antigenic proteoglycan.    
     
     
         7 . The composition of  claim 1 , wherein said antigenic component is an  N. meningitidis protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein.    
     
     
         8 . The composition of  claim 1 , wherein said antigenic component is selected from the group consisting of Cu,Zn-superoxide dismutase; neisserial surface protein A (NspA); porA; OMP85; FrpB; PilQ; Hsf; HemK; sodC; mafA; N-acetyl glutamate synthetase; and macrophage infectivity potentiator-related protein. 
     
     
         9 . The composition of  claim 1 , wherein said antigenic component is a peptide selected from the group consisting of SEQ ID NOS: 2; 4; 6; 8; 10; 12; 14; 16; 18; 20; 22; 24; 26; 28; 30; 32; 34; 36; 38; 40; 42; 44; 46; 48; 50; 52; 54; 56; 58; 60; 62; 64; 66; 68; 70; and 72. 
     
     
         10 . The composition of  claim 2 , wherein said outer membrane vesicles are from a first strain of  N. meningitidis  and said antigenic component is from a second strain of  N. meningitidis  different from the first, further comprising a pharmaceutically acceptable carrier. 
     
     
         11 . A vaccine composition comprising outer membrane vesicles from a first strain of  N. meningitidis , as well as an antigenic component from a second strain of  N. meningitidis  different from the first, and a pharmaceutically acceptable carrier. 
     
     
         12 . The vaccine composition of  claim 11 , wherein the antigenic component is selected from the group consisting of Cu,Zn-superoxide dismutase; neisserial surface protein A (NspA); porA; OMP85; FrpB; PilQ; Hsf; HemK; sodC; mafA; N-acetyl glutamate synthetase; and macrophage infectivity potentiator-related protein. 
     
     
         13 . The vaccine composition of  claim 11 , wherein the antigenic component is a peptide selected from the group consisting of SEQ ID NOS: 2; 4; 6; 8; 10; 12; 14; 16; 18; 20; 22; 24; 26; 28; 30; 32; 34; 36; 38; 40; 42; 44; 46; 48; 50; 52; 54; 56; 58; 60; 62; 64; 66; 68; 70; and 72. 
     
     
         14 . A method of manufacture of a composition, comprising:
 (a) extracting an antigenic component from an outer membrane of a bacteria, and preparing an aqueous solution of said antigenic component;   (b) extracting outer membrane vesicles from a culture of  N. meningitidis , and preparing an aqueous solution of said outer membrane vesicles;   (c) obtaining a pharmaceutically acceptable carrier; and   (d) admixing the solution prepared in (a), the solution prepared in (b) and the carrier obtained in (c).   
     
     
         15 . The method of  claim 14 , wherein said antigenic component is from a first strain of  N. meningitidis , and said outer membrane vesicles are from a second strain of  N. meningitidis  different from the first. 
     
     
         16 . The method of  claim 15 , wherein said strains of  N. meningitidis  are selected from the group consisting of K454; B16B6; L91 113; L91 705; L2412; 570059; L93 658; LAC 2043; H44/76; L91 543; L93 3215; A188/83; A321/83; L90-1252; L90-1493; LE-187; Y92-1009; Y92-1011; Y92-1012; Y92-1013; L93-1774; L93-1869; L932086; L93-2411; L93-2539; 310555; 310626; L94/4931; F82/38; C-11(60E); N16; N91; N96; N97; MC58; MC58 sod b-; MC58 sod c-; MC58 sod bc-; M97-251637; M97-251622; M97-251293; M97-251288; M97-251224; M97-251023; M97-250294; M97-250293; M97-250116; M96-255488; M96-255440; M96-254823; M96-253948; M96-253950; M96-255789; PhoP mutant; HG 09.02.76 Immunotype L3,7,9; ES 27.01.75 Immunotype L3,7,9; WY 23.01.65 Immunotype L3,7,9; MN 23.02.71; PKD 31.08.80; SG 01.03.76; KH 21.05.67; JK 02.10.80; KN 01.06.77; SR 20.09.78; AG 07.12.73 Immunotype L3,7,9; SSt 19.07.78; TM 16.12.79; SME 16.01.58; CG 21.10.77 Immunotype L3,7,9; TB 12.03.74 Immunotype L3,7,9; FH 29.11.73 Immunotype L3,7,9+L1,8,1; TF 17.04.76 Immunotype L3,7,9; CM 08.08.77 Immunotype L3,7,9; KS 08.07.73 Immunotype L3,7,9; AS 06.11.77; LL 03.01.75 Immunotype L3,7,9; SSk 29.07.76 Immunotype L3,7,9; GKY 24.05.66 Immunotype L3,7,9; JHO 24.08.77 Immunotype L3,7,9; SGW 13.12.72 Immunotype L3,7,9; AKS 28.09.75; MV 31.10.76; ID 15.02.74; SJ 28.06.83; JU 10.12.46; M99-240124; M99-240362; M99-240782; M99-241440; M99-241503; M99-241735; M99-242020; M99-242180; MC58 promo-; MC58 448.1 nov.; MC58 432 nov; MC58 418 nov; MC58 401.2 nov; MC58424 nov; MC58 423.1 nov; MC58 frp; MC58 abc; MC58 frp; MC58 comA; MC58 ner; MC58 hsp; M96 255789; M96 255789; M96 255789; MC58; AR; LV; BM; JB; GN; SD (70942); G2379; L352; SH151; SH1789; SH1497; SH1602; SH 1717; SH148; L911134; SH155; SH161; J1755; SH4074; SH3424; J1455; SH1052; SH1114; M96 255789; M97-252455; M97-252535; M99-250591; M99-240706; M97-252005; Y92-1009; 9476; Z5005; Z6835; Z6244; Z3524; Z6466; Z8948; Z6904; Z4662; Z4673; Z7990; Z4683; Z4667; Z4707; Z6793; Z6784; Z7109; M97-251336; M97-252086; M97-252234; M97-252239; M97-252416; M97-252638; M98-251221; M98-251544; KG106; L91-543; and JNPHOPKO. 
     
     
         17 . The method of  claim 14 , wherein said antigenic component is an  N. meningitidis  antigenic protein. 
     
     
         18 . The method of  claim 14 , wherein said antigenic component is an  N. meningitidis  antigenic proteoglycan. 
     
     
         19 . The method of  claim 14 , wherein said antigenic component is an  N. meningitidis  protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein. 
     
     
         20 . The method of  claim 14 , wherein said antigenic component is selected from the group consisting of Cu,Zn-superoxide dismutase; neisserial surface protein A (NspA); porA; OMP85; FrpB; PilQ; Hsf; HemK; sodC; mafA; N-acetyl glutamate synthetase; and macrophage infectivity potentiator-related protein. 
     
     
         21 . The method of  claim 14 , wherein said antigenic component is a peptide selected from the group consisting of SEQ ID NOS: 2; 4; 6; 8; 10; 12; 14; 16; 18; 20; 22; 24; 26; 28; 30; 32; 34; 36; 38; 40; 42; 44; 46; 48; 50; 52; 54; 56; 58; 60; 62; 64; 66; 68; 70; and 72. 
     
     
         22 . A method of manufacture of a composition, comprising:
 (a) recombinantly expressing a DNA that encodes an antigenic component in a bacteria;   (b) extracting said antigenic component from the outer membrane of said bacteria, and preparing an aqueous solution of said antigenic component;   (c) extracting outer membrane vesicles from a culture of  N. meningitidis , and preparing an aqueous solution of said outer membrane vesicles;   (d) obtaining a pharmaceutically acceptable carrier; and   
       admixing the solution prepared in (b), the solution prepared in (c) and the carrier obtained in (d). 
     
     
         23 . The method of  claim 22 , wherein said bacteria is a strain of  N. meningitidis.    
     
     
         24 . A method of manufacture of a composition, comprising:
 (a) recombinantly expressing a DNA that encodes an antigenic component in  N. meningitidis;      (b) extracting outer membrane vesicles from said  N. meningitidis, and preparing an aqueous solution of said outer membrane vesicles, wherein said outer membrane vesicles comprise said antigenic component;      (c) obtaining a pharmaceutically acceptable carrier; and   a. (d) admixing the solution prepared in (b), with the carrier obtained in (c).   
     
     
         25 . The method of  claim 24 , wherein said antigenic component is an  N. meningitidis  protein selected from the group consisting of a surface antigen, a periplasmic protein, a superoxide dismutase, and a glycoprotein. 
     
     
         26 . The method of  claim 24 , wherein said antigenic component is an  N. meningitidis  protein selected from the group consisting of Cu,Zn-superoxide dismutase; neisserial surface protein A (NspA); porA; OMP85; FrpB; PilQ; Hsf; HemK; sodC; mafA; N-acetyl glutamate synthetase; and macrophage infectivity potentiator-related protein. 
     
     
         27 . The method of  claim 24 , wherein said antigenic component is an  N. meningitidis  protein selected from the group consisting of SEQ ID NOS: 2; 4; 6; 8; 10; 12; 14; 16; 18; 20; 22; 24; 26; 28; 30; 32; 34; 36; 38; 40; 42; 44; 46; 48; 50; 52; 54; 56; 58; 60; 62; 64; 66; 68; 70; and 72. 
     
     
         28 . A method of preventing  N. meningitidis  infection in an animal, comprising administering an effective dose of a composition comprising an outer membrane vesicle and an antigenic component selected from the group consisting of Cu,Zn-superoxide dismutase; neisserial surface protein A (NspA); porA; OMP85; FrpB; PilQ; Hsf; HemK; sodC; mafA; N-acetyl glutamate synthetase; and macrophage infectivity potentiator-related protein, and a pharmaceutically acceptable carrier. 
     
     
         29 . The method of  claim 28 , wherein said antigenic component is from a first strain of  N. meningitidis , and said outer membrane vesicles are from a second strain of  N. meningitidis  different from the first 
     
     
         30 . The method of  claim 28 , wherein said animal is a mammal. 
     
     
         31 . The method of  claim 28 , wherein said animal is a human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.